AbbVie Inc. (BIT:1ABBV)

Italy flag Italy · Delayed Price · Currency is EUR
187.00
-2.40 (-1.27%)
At close: Feb 11, 2026
Market Cap330.35B +11.0%
Revenue (ttm)52.09B +8.6%
Net Income3.60B -1.2%
EPS2.01 -1.3%
Shares Outn/a
PE Ratio91.78
Forward PE15.18
Dividend5.75 (3.04%)
Ex-Dividend DateJan 15, 2026
Volume21
Average Volume49
Open186.00
Previous Close189.40
Day's Range185.20 - 186.60
52-Week Range149.00 - 208.00
Betan/a
RSI51.82
Earnings DateFeb 4, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2012
Employees 55,000
Stock Exchange Borsa Italiana
Ticker Symbol 1ABBV
Full Company Profile

Financial Performance

In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.23 billion, a decrease of -0.28%.

Financial numbers in USD Financial Statements